Grace Therapeutics (GRCE) 10% Owner Inc. Buys $11K of Stock

Opaleye Management Inc. has increased its stake in Grace Therapeutics, Inc. (NASDAQ: GRCE) by buying 5,340 shares on October 9, 2026. This transaction was valued at approximately $10,918.16, with the shares purchased at an average price of $2.04 each.

Inside Opaleye Management's Trade

Opaleye Management, a 10% owner of Grace Therapeutics, continues to show confidence in the company with this recent purchase. This buy comes after several earlier transactions, including a notable buy of 60,490 shares on October 5, 2026, which was valued at about $123,819.

Other Institutional Activity in Grace Therapeutics

Other institutional investors have also been active in Grace Therapeutics. Eversept Partners, LP increased its holdings by 16,268 shares, bringing its total to 772,900 shares worth about $1.46 million. Vanguard Capital Management LLC added 10,042 shares, ending with 411,714 shares valued at approximately $778,139. Citadel Advisors LLC made a significant move by increasing its stake by 250,999 shares, totaling 349,740 shares worth about $661,008.

Grace Therapeutics, Inc. Stock Down 3.1%

As of October 16, 2026, Grace Therapeutics trades at about $1.89, which is below its 50-day moving average of $2.12 and significantly below its 200-day moving average of $2.91. The stock is currently about 63.5% below its 52-week high of $5.18, but it remains above its 52-week low of $1.79.

Recent Earnings

Grace Therapeutics reported a trailing twelve-month revenue of $0, with a net margin of 0.0%. The company has a current ratio of 11.47, suggesting good short-term financial health. The next earnings report is expected to provide further insight into its financial performance.

Insider Buying and Selling at Grace Therapeutics, Inc.

Opaleye Management has been active in the market, with multiple transactions. On September 23, 2026, it bought 15,089 shares at $2.10, totaling $31,687. Two days later, on September 29, it purchased another 7,849 shares at $2.09, valued at $16,404. These purchases indicate a sustained commitment to increasing their stake in Grace Therapeutics.

About Grace Therapeutics

Grace Therapeutics, Inc. engages in developing and commercializing pharmaceutical products for rare and orphan diseases, primarily in Canada. Its lead product is GTX-104, an injectable treatment for aneurysmal subarachnoid hemorrhage. The company, headquartered in Princeton, NJ, has a small team of five employees and operates in the healthcare and biotechnology sectors.

Bottom Line

Opaleye Management's recent purchase is a continuation of its strategy to build a larger position in Grace Therapeutics. Investors will be watching for the next earnings report and any further insider activity, as these could indicate how the company is navigating the market challenges ahead.